Post Traumatic Stress Disorder Clinical Trial
— APCIPOfficial title:
Adolescent BREATHE Primary Care Intervention for PTSD (PCIP) Randomized Feasibility Trial
There are three research questions: (1) whether the Primary Care Intervention for PTSD (PCIP) improves health outcomes; (2) whether and how the PCIP can be sustainably delivered via telehealth; and (3) how PCIP compares to treatment as usual (TAU) participants. The mixed methods randomized feasibility trial of the protocol will be measured by the RE-AIM framework (Reach, Effectiveness, Adoption, Implementation, Maintenance) (n=44 patients and their care givers). We will collect data on patient, caregiver, and clinic staff participation, retention, and satisfaction (Reach and Adoption), change in hypothesized treatment mechanisms and symptoms (Effectiveness), and facilitators and barriers to intervention delivery and fidelity (Implementation). We will, 1. Assess the reach and adoption of the protocol by analyzing quantitative data on patient and clinic staff participation, retention, and satisfaction; 2. Explore the effectiveness of the protocol through medical record review, quantitative assessments at baseline and post-treatment, and semi-structured qualitative interviews at baseline and post-treatment to: 3. Evaluate the implementation of the screening and intervention protocol with post-intervention semi-structured qualitative interviews to assess facilitators and barriers to intervention delivery, quantitative fidelity scales, observation of screening, and review of intervention audio recordings to assess fidelity to the protocol and intervention process.
Status | Recruiting |
Enrollment | 44 |
Est. completion date | July 30, 2025 |
Est. primary completion date | December 20, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 12 Years to 22 Years |
Eligibility | Inclusion Criteria: 1. Patient referred to the SHARK Program 2. Patients must be at least 12 years old 3. Screened for probable PTSD on UCLA RI, or at provider discretion of clinical relevancy. 4. If patient is under 18 years old, the patient's legal guardian is able and willing to provide informed consent for the patient to participate in the study; 5. Patient is able to complete study activities in English. Exclusion Criteria: 1. Suicidal ideation with a plan within the last two weeks or a suicide attempt within the past 30 days; 2. Inability to provide informed consent or assent, and/or complete procedures in English. |
Country | Name | City | State |
---|---|---|---|
United States | University of California Los Angeles | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
University of California, Los Angeles |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in PTSD Knowledge | Changes in levels of PTSD Knowledge measured by the PTSD Knowledge Test (0-14, higher scores indicating more PTSD knowledge) | Day 0 baseline, 10 months | |
Primary | Change in Trauma-Related Cognitions | Changes in post-traumatic cognitions measured by the Post-Traumatic Cognitions Inventory (1-7, Higher scores indicating more post traumatic cognitions) | Day 0 baseline, 10 months | |
Primary | Change in Self-Reported Arousal | Changes in PTSD related arousal levels measured by the Composite Autonomic Symptom Score (COMPASS-31; 0-100 total, Higher scores indicating higher arousal) | Day 0 baseline, 10 months | |
Primary | Change in Stress Management Skill Use | Changes in PTSD related arousal levels measured Measure of Adolescent Coping Strategies (MACS; Total 0-102, higher scores indicate higher use of specified coping), and use of the breathing retraining techniques as measured by self-reports during in-session review. | Day 0 baseline, 10 months | |
Primary | Intervention Implementation and Acceptability | Qualitative interviews will include questions regarding acceptability of treatment including treatment via telehealth. Additionally, data will be collected regarding participant completion of therapy, no show rates, barriers to treatment, and attendance. Additionally, study therapists will complete qualitative and quantitative measures regarding intervention delivery feasibility and study protocols. | Day 0 baseline, 10 months | |
Secondary | Change in PTSD Symptoms | Changes in PTSD related symptoms measured by the UCLA Child/Adolescent PTSD Reaction Index for DSM-5 Brief Screen (total 0-44; Higher scores indicate higher likelihood of PTSD and symptom-related distress and impairment) | Day 0 baseline, 10 months | |
Secondary | Change in Trauma Symptoms | Changes in trauma related symptoms measured by The Child PTSD Symptom Scale (CPSS-5-SR) Self Report (total 0-80, Higher scores indicated greater symptom severity). | Day 0 baseline, 10 months | |
Secondary | Change in Adverse Childhood Experiences | Changes in Adverse Childhood Experiences measured by the Pediatric ACEs and Related Life Events Screener (PEARLS; 0-19, higher scores indicate higher risk of traumatic stress. | Day 0 baseline, 10 months | |
Secondary | Change in Depression Symptoms | Changes in depression symptoms measured by the Center for Epidemiologic Studies Depression Scale (CES-DC) Self Report (total 0-60, Higher scores indicate higher symptom severity). | Day 0 baseline, 10 months | |
Secondary | Change in Depression Symptoms | Changes in depression symptoms measured by the Patient Health Questionnaire (PHQ-9;0-27; Higher scores indicate higher symptoms and likelihood of depression) | Day 0 baseline, 10 months | |
Secondary | Change in Anxiety Symptoms | Changes in anxiety symptoms measured by the Revised Children's Anxiety and Depression Scale (RCADS) Self Report (total 0-141, Higher scores indicating higher symptom severity). | Day 0 baseline, 10 months | |
Secondary | Change in Functional Impairment | Changes in functional impairment measured by The Columbia Impairment Scale (C.I.S.; 0-52, Higher scores indicate greater impairment). | Day 0 baseline, 10 months | |
Secondary | Change in pro-inflammatory cytokine biomarkers | Changes in pro-inflammatory cytokines including TNF-a, IL-6, IFN-? and IL-1ß will be analyzed from Dried Blood Spots (DBS) | Day 0 baseline, 10 months | |
Secondary | Change in pro-inflammatory transcription factor activation | Changes in pro-inflammatory transcription factor activation including NF-?B/Rel will be analyzed from Dried Blood Spots (DBS) | Day 0 baseline, 10 months | |
Secondary | Change in Substance Use | Changes in substance use and misuse measured by CRAFFT Adolescent Substance Use Screen (0-9, Higher scores indicate higher risk for substance misuse) | Day 0 baseline, 10 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05915013 -
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
|
Phase 1 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Recruiting |
NCT05934175 -
Intensive Treatment Versus Standard Weekly Prolonged Exposure for Adults With Post-Traumatic Stress Disorder
|
N/A | |
Recruiting |
NCT05934162 -
Efficacy of Internet-delivered Cognitive-behavior Therapy for PTSD
|
N/A | |
Completed |
NCT04460014 -
Simple Cognitive Task Intervention After Trauma During COVID-19 In Hospital Staff EKUT-P RCT
|
N/A | |
Completed |
NCT05877807 -
Effect of Baclofen to Prevent Post-Traumatic Stress Disorder
|
||
Active, not recruiting |
NCT05992649 -
The Effect of Aquatic Physiotherapy on Veterans Suffering From PTSD - a 40-week Pilotproject
|
N/A | |
Terminated |
NCT04404712 -
FAAH Availability in Psychiatric Disorders: A PET Study
|
Early Phase 1 | |
Not yet recruiting |
NCT05331534 -
Effect of Attentional Therapy on Post-traumatic Stress Disorder
|
N/A | |
Not yet recruiting |
NCT03649607 -
Accelerated Resolution Therapy for HIV Positive African, Caribbean and Black
|
N/A | |
Not yet recruiting |
NCT04076215 -
Biochemical and Physiological Response to Stressogenic Stimuli
|
N/A | |
Not yet recruiting |
NCT02545192 -
A Pilot Study of Low Field Magnetic Stimulation in PTSD: Three Daily Treatments
|
Phase 1 | |
Completed |
NCT02329418 -
Written Document to Assist Family During Decision of Withholding and Withdrawing Life-sustaining Therapies in the Intensive Care Unit
|
N/A | |
Active, not recruiting |
NCT00978484 -
A Head-to-head Comparison of Virtual Reality Treatment for Post Traumatic Stress Disorder
|
Phase 3 | |
Completed |
NCT00760734 -
Hyperbaric Oxygen Therapy (HBOT) in Chronic Traumatic Brain Injury (TBI)/Post Concussion Syndrome (PCS) and TBI/Post-Traumatic Stress Disorder (PTSD)
|
Phase 1 | |
Completed |
NCT03278171 -
Early Detection of Patients at Risk of Developing a Post-traumatic Stress Disorder After a Stay in Intensive Care Unit
|
||
Recruiting |
NCT05874362 -
People Bereaved by Violent Death : Negative Event Biases and Temporal Perception
|
N/A | |
Terminated |
NCT03898843 -
Assisted Animal Therapy: ReAnimal
|
N/A | |
Recruiting |
NCT04747379 -
Psychological Effect of Explicit Recall After Sedation (PEERS)
|
||
Completed |
NCT03248167 -
Cannabidiol as a Treatment for AUD Comorbid With PTSD
|
Phase 1/Phase 2 |